Status:
ACTIVE_NOT_RECRUITING
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by...
Detailed Description
This is an open-label study to provide continued access to treatment for eligible participants who continue to derive clinical benefit as determined by the investigator from study intervention(s) in a...
Eligibility Criteria
Inclusion
- Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study
- Participants must agree to follow the reproductive criteria
- Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol
Exclusion
- Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study
Key Trial Info
Start Date :
July 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05226871
Start Date
July 7 2022
End Date
December 31 2026
Last Update
November 25 2025
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Medical Center at Mission Bay
San Francisco, California, United States, 94158
2
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230022
3
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
4
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510000